Tyruko
Generic name: Natalizumab-sztn
Dosage form: injectable injection
Drug class:
Selective immunosuppressants
Usage of Tyruko
Tyruko (natalizumab-sztn) is an injectable integrin receptor antagonist that is a biosimilar to Tysabri (natalizumab) that may be used to treat adults with relapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease) or moderate to severe Crohn's disease (usually after other treatments have been tried).
A biosimilar is a biological product that is like a reference biologic (in this case Tysabri) and for which there are no clinically meaningful differences in terms of safety, purity, and potency. A biosimilar is not considered a “generic” because they are made from living cells rather than chemicals, making them naturally variable, and they are expensive to make. Generic drugs contain identical medicinal ingredients to their reference products and are cheap to make.
Tyruko was FDA-approved on August 24, 2023. It covers all the same indications as the reference product, Tysabri.
Tyruko side effects
Get emergency medical help if you have signs of an allergic reaction to Tyruko such as hives, a rash, wheezing, difficulty breathing, or swelling of your face, lips, tongue, or throat.
Some allergic reactions may occur during the injection. Tell your caregiver right away if you feel dizzy, nauseated, light-headed, itchy, cold, or sweaty, or if you have chest pain, trouble breathing, or swelling in your face.
Tyruko may cause serious viral infections of the brain or spinal cord that can lead to disability or death. Call your doctor right away if you have any of the following symptoms during treatment with Tyruko or up to 6 months after your last dose (these symptoms may start gradually and get worse quickly):
Also, call your doctor at once if you have:
Common Tyruko side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Before taking Tyruko
You should not receive Tyruko if you are allergic to natalizumab, or if you have ever had PML.
Your doctor will test you for antibodies to the John Cunningham Virus (JCV). This is a common virus that has infected almost half of the population, although most people are unaware that they have had it. It does not usually cause problems for healthy people but it can be dangerous for those with a weakened immune system.
Tyruko is only available from a certified pharmacy under a special program called the Tyruko REMS Program. You must be registered in the program and understand the risks and benefits of taking this medicine.
To make sure this medicine is safe for you, tell your doctor if you have ever had:
Tyruko can cause harm to an unborn baby and it should not be used while pregnant. Tell your doctor if you are pregnant or plan to become pregnant. Call your doctor right away if you inadvertently become pregnant.
It may not be safe to breastfeed while using Tyruko because it has been detected in human milk. Ask your doctor about any risks.
Tyruko is not approved for use by anyone younger than 18 years old.
Relate drugs
- Abrocitinib
- Alefacept
- Amevive
- Anifrolumab
- Anifrolumab-fnia
- Anti-thymocyte globulin rabbit
- Atgam equine
- Aubagio
- Avacopan
- Muromonab-cd3
- Mycophenolate (Intravenous)
- Mycophenolate mofetil
- Mycophenolate mofetil oral/injection
- Mycophenolic acid
- Myfortic
- Bafiertam
- Belatacept
- Belimumab
- Belumosudil
- Benlysta
- Cellcept
- Cellcept (Mycophenolate Intravenous)
- Cellcept (Mycophenolate mofetil Oral)
- Cibinqo
- Dimethyl fumarate
- Diroximel fumarate
- Eculizumab
- Emapalumab
- Emapalumab-lzsg
- Empaveli
- Enjaymo
- Entyvio
- Fingolimod
- Gamifant
- Gilenya
- Inebilizumab
- Inebilizumab-cdon
- Lymphocyte immune globulin, anti-thymocyte equine
- Mayzent
- Monomethyl fumarate
- Natalizumab
- Natalizumab-sztn
- Nulojix
- Omalizumab
- Orthoclone OKT 3
- Ozanimod
- Pegcetacoplan
- Pegcetacoplan (Subcutaneous)
- Ponesimod
- Ponvory
- Ponvory Starter Pack
- Pozelimab-bbfg
- Raptiva
- Ravulizumab
- Ravulizumab-cwvz
- Rezurock
- Saphnelo
- Siponimod
- Soliris
- Sutimlimab
- Sutimlimab-jome
- Tascenso ODT
- Tavneos
- Tecfidera
- Teriflunomide
- Tezepelumab
- Tezepelumab-ekko
- Tezspire
- Tezspire Pre-filled Pen
- Tezspire Pre-filled Syringe
- Thymoglobulin
- Thymoglobulin rabbit
- Tyruko
- Tyruko (Natalizumab Intravenous)
- Tyruko (Natalizumab-sztn Intravenous)
- Tysabri
- Ultomiris
- Uplizna
- Vedolizumab
- Veopoz
- Vumerity
- Xolair
- Zeposia
How to use Tyruko
Tyruko is given as an IV infusion into a vein, over one hour, usually once every 4 weeks. A healthcare provider will give you this injection.
The usual dose is 300mg and Tyruko must be given slowly, which is why the IV infusion can take at least 1 hour to complete. You will be watched closely for at least 1 hour after receiving the infusion, to make sure you do not have an allergic reaction to the medication. An allergic reaction can occur up to 2 hours or longer after your infusion.
Before your first dose, your doctor may recommend an MRI to make sure you do not have any signs of a brain infection.
Tyruko can weaken your immune system. You may get infections more easily, even serious or fatal infections.
You will need frequent blood tests. You may also need a brain scan or spinal tap (lumbar puncture) if you develop signs of a brain infection.
Your doctor must check you every 3 to 6 months for signs of serious infection. Your doctor may also want to check you for several weeks after you stop using this medicine.
Tell any doctor who treats you that you are using Tyruko.
Your doctor will determine every 6 months whether you should continue on treatment, and if so, will authorize treatment for another 6 months.
Warnings
Tyruko increases the risk of progressive multifocal leukoencephalopathy (PML), a viral infection of the brain that usually occurs in immunosuppressed people. This can lead to severe disability and death. Risk factors include using presence of John Cunningham Virus (JCV) antibodies, duration of treatment beyond 2 years, and prior use of immunosuppressants. Because of this risk, Tyruko is only available through a restricted distribution program called the Tyruko REMS Program. Call your doctor right away if you have a sudden fever, severe headache, confusion, memory problems, vision changes, eye pain, weakness on one side of your body, or problems with using your arms or legs. These symptoms may start gradually and get worse quickly.
Life-threatening infections, including herpes encephalitis, meningitis, and acute retinal necrosis have occurred in patients receiving natalizumab. Call your doctor right away if you have any change in your mental state, decreased vision, weakness on one side of your body, or problems with speech or walking. These symptoms may start gradually and get worse quickly.
Significant liver injury, including liver failure requiring transplant, has occurred. Call your doctor at once if you develop any symptoms of liver damage, such as nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, or jaundice (yellowing of the skin or eyes).
Tyruko can increase your risk of infection. Call your doctor right away if you develop any signs of infection such as fever, chills, sore throat, cough, stuffy nose, redness, pain, swelling, or painful urination.
There is a risk of severe hypersensitivity reactions, such as anaphylaxis, with Tyruko. It should be permanently discontinued if these occur.
Thrombocytopenia (very low platelet counts) can occur with natalizumab. Your doctor will conduct regular blood tests and monitor you for bleeding abnormalities.
In Crohn’s disease, this drug should not be used with concomitant immunosuppressants (such as 6-mercaptopurine, azathioprine, cyclosporine, and methotrexate) or inhibitors of TNF-alpha.
What other drugs will affect Tyruko
Tell your doctor about all your current medicines and any you start or stop using, especially drugs that weaken the immune system such as cancer medicine, steroids, and medicines to prevent organ transplant rejection.
Other drugs may interact with natalizumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions